Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$3.54B
Close$
$55.30
32.1% upside
Current Fair Value
32.1% upsideUndervalued by 32.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.54 Billion |
|---|---|
| Enterprise Value | $3.13 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-7.96 |
| Beta | 1.17 |
| Outstanding Shares | 83,133,341 |
| Avg 30 Day Volume | 757,303 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.78 |
|---|---|
| PEG | -141.09 |
| Price to Sales | 8.37 |
| Price to Book Ratio | 41.87 |
| Enterprise Value to Revenue | 7.07 |
| Enterprise Value to EBIT | -5.39 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis